Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | MAX | P61244 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152661 | 1.00 | PRSS1 (0.53) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL6209803 | 1.00 | PRSS1 (0.53) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL5152657 | 1.00 | PRSS1 (0.53) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL4717487 | 0.89 | MYC (0.64) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL5155524 | 0.87 | AR (0.55) | PRSS1LMNA | |
| SCHEMBL7690520 | 0.86 | HCAR3 (0.56) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL7697860 | 0.86 | HCAR3 (0.56) | PRSS1HCAR3MYCMAXPLA2G4B | |
| SCHEMBL1402203 | 0.82 | MAPT (0.65) | PRSS1HCAR3PLA2G4BCASP6LMNA | |
| SCHEMBL28317046 | 0.82 | XDH (0.57) | PRSS1HCAR3MYCMAXPLA2G4B | |
| Hydrochloric Acid SCHEMBL11776063 | 0.81 | MAPT (0.64) | PRSS1HCAR3PLA2G4BCASP6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | PRSS1 2539/4885HCAR3 1328/4885MYC 707/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | PRSS1 2449/4885HCAR3 1336/4885MYC 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.